- Home
- EYPT vs RPAY Comparison
EYPT vs RPAY Comparison
Compare EYPT & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | RPAY |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | 214 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Business Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 291.0M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EYPT | RPAY |
|---|---|---|
| Price | $3.33 | $3.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $31.80 | $5.53 |
| AVG Volume (30 Days) | ★ 3.3M | 352.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $309,261,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | $3,115.57 | $4.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.42 | $2.30 |
| 52 Week High | $19.11 | $5.39 |
Technical Indicators
Market Signals| Indicator | EYPT | RPAY |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 48.17 |
| Support Level | N/A | $3.47 |
| Resistance Level | $14.72 | $3.96 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 5.02 | 51.92 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About RPAY Repay Holdings Corporation
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.